These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Agreement with evidence for tissue Plasminogen Activator use among emergency physicians: a cross-sectional survey. Grady AM; Bryant J; Carey ML; Paul CL; Sanson-Fisher RW; Levi CR BMC Res Notes; 2015 Jun; 8():267. PubMed ID: 26111807 [TBL] [Abstract][Full Text] [Related]
25. Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation. Lawson TR; Brown IE; Westerkam DL; Blackhurst DW; Sternberg S; Leacock R; Nathaniel TI Restor Neurol Neurosci; 2015; 33(3):301-8. PubMed ID: 25698111 [TBL] [Abstract][Full Text] [Related]
26. Knowledge and Attitudes of Saudi Emergency Physicians toward t-PA Use in Stroke. Al Khathaami AM; Aloraini H; Almudlej S; Al Issa H; Elshammaa N; Alsolamy S Neurol Res Int; 2018; 2018():3050278. PubMed ID: 30364030 [TBL] [Abstract][Full Text] [Related]
27. Rupture of an Occult Intracranial Mycotic Aneurysm after Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke. Glenn J; Strecker-McGraw M; McGraw I; Jabbar K; James NA; Stone CK J Emerg Med; 2017 Nov; 53(5):717-721. PubMed ID: 28988732 [TBL] [Abstract][Full Text] [Related]
29. Why don't more patients receive intravenous rt-PA for acute stroke? Lyden P Expert Rev Neurother; 2015 Jun; 15(6):571-4. PubMed ID: 25938622 [TBL] [Abstract][Full Text] [Related]
30. Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists. Rybinnik I; Mullen MT; Messe S; Kasner SE; Cucchiara B J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):1312-6. PubMed ID: 23313461 [TBL] [Abstract][Full Text] [Related]
31. Eligibility determination for intravenous thrombolysis based on radiology interpretation report of the head CT scan in patients with acute ischemic stroke. Hassan AE; Majidi S; Janjua NA; Chaudhry SA; Tekle WG; Grigoryan M; Qureshi AI J Neuroimaging; 2014; 24(4):349-53. PubMed ID: 24015702 [TBL] [Abstract][Full Text] [Related]
32. Lack of t-PA use for acute ischemic stroke in a community hospital: high incidence of exclusion criteria. Engelstein E; Margulies J; Jeret JS Am J Emerg Med; 2000 May; 18(3):257-60. PubMed ID: 10830678 [TBL] [Abstract][Full Text] [Related]
33. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Chiu D; Krieger D; Villar-Cordova C; Kasner SE; Morgenstern LB; Bratina PL; Yatsu FM; Grotta JC Stroke; 1998 Jan; 29(1):18-22. PubMed ID: 9445322 [TBL] [Abstract][Full Text] [Related]
34. Factors associated with the administration of tissue plasminogen activator for acute ischemic stroke. Kunisawa S; Kobayashi D; Lee J; Otsubo T; Ikai H; Yokota C; Minematsu K; Imanaka Y J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):724-31. PubMed ID: 23910512 [TBL] [Abstract][Full Text] [Related]
35. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience. Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460 [TBL] [Abstract][Full Text] [Related]
36. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384 [TBL] [Abstract][Full Text] [Related]
37. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study. Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252 [TBL] [Abstract][Full Text] [Related]
38. Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: intracranial bleeding associated with the treatment of ischemic stroke: thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator. Suzuki Y; Nagai N; Umemura K J Pharmacol Sci; 2011; 116(1):25-9. PubMed ID: 21498957 [TBL] [Abstract][Full Text] [Related]
39. Analysis of tissue plasminogen activator eligibility by sex in the Greater Cincinnati/Northern Kentucky Stroke Study. Madsen TE; Khoury JC; Alwell KA; Moomaw CJ; Kissela BM; De Los Rios La Rosa F; Woo D; Adeoye O; Flaherty ML; Khatri P; Ferioli S; Kleindorfer D Stroke; 2015 Mar; 46(3):717-21. PubMed ID: 25628307 [TBL] [Abstract][Full Text] [Related]
40. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator? Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]